Inflammation targeted nanomedicines: Patents and applications in cancer therapy

被引：11

作者：

Praveen, Thaggikuppe Krishnamurthy ^{[1
]}

Gangadharappa, Hosahalli Veerabhadrappa ^{[2
]}

Lila, Amr Selim Abu ^{[3
,4
]}

Moin, Afrasim ^{[4
]}

Mehmood, Khalid ^{[5
]}

Krishna, Kamsagara Linganna ^{[6
]}

Hussain, Talib ^{[7
]}

Alafnan, Ahmed ^{[7
]}

Shakil, Shazi ^{[8
,9
,10
]}

Rizvi, Syed Mohd Danish ^{[4
]}

机构：

[1] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmacol, Ooty 643001, Tamil Nadu, India

[2] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru 570015, Karnataka, India

[3] Zagazig Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Zagazig, Egypt

[4] Univ Hail, Coll Pharm, Dept Pharmaceut, Hail, Saudi Arabia

[5] Abbottabad Univ Sci & Technol, Dept Pharm, Havelian, Pakistan

[6] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmacol, Mysuru 570015, Karnataka, India

[7] Univ Hail, Coll Pharm, Dept Pharmacol & Toxicol, Hail, Saudi Arabia

[8] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi Arabia

[9] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah, Saudi Arabia

[10] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia

来源：

SEMINARS IN CANCER BIOLOGY | 2022年 / 86卷

关键词：

Cancer; Nano; -therapeutics; Anti-inflammatory nanomedicines; Patents; Clinical translation; MEMBRANE-CAMOUFLAGED NANOPARTICLES; REGULATORY T-CELLS; DRUG-DELIVERY; IN-VIVO; DENDRITIC CELLS; SUPPRESSOR-CELLS; LOTEPREDNOL ETABONATE; LIPID NANOPARTICLES; PHARMACOKINETICS; VESICLES;

D O I：

10.1016/j.semcancer.2022.04.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Evident role of inflammation in cancer development and progression prompted the application of antiinflammatory medications as a therapeutic strategy. The major bottleneck for the anti-inflammatory drugs is targeted delivery to the cancerous cell. Nanotechnology has provided safe and effective way for targeted cancer therapy. However, the complex and heterogeneous traits of cancer, incomplete information on fate and behavior of nanomedicines in human body, and lack of large-scale commercial production have slowed down the pace of nanomedicines development. To shift the paradigm from conventional cancer therapeutics to anti-inflammatory nano-therapeutics, thorough understanding of the strategies, progress, success, challenges and future perspectives are needed. The present review highlights all these aspects in addition to innovations patented on them. In fact, patent plays a vital role in protection of innovations, and further translation of lab-scale outcomes into bedside medications. Thus, the review introspects and recognizes the glitches in successful clinical translation of anti-inflammatory nanomedicines.

引用

页码：645 / 663

页数：19

共 187 条

[1]

Abe Hideaki, 2021, Medicines (Basel), V8, DOI [10.3390/medicines8040017, 10.3390/medicines8040017]

[2]

Adcock IA., 2004, Drug Discov Today, V1, P321

[3] Development and evaluation of polymeric nanocapsules for cirsiliol isolated from Jordanian Teucrium polium L. as a potential anticancer nanomedicine [J].

Al-Shalabi, Eveen ;

Alkhaldi, Muzn ;

Sunoqrot, Suhair .

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 56

[4] Tumour-on-a-chip provides an optical window into nanoparticle tissue transport [J].

Albanese, Alexandre ;

Lam, Alan K. ;

Sykes, Edward A. ;

Rocheleau, Jonathan V. ;

Chan, Warren C. W. .

NATURE COMMUNICATIONS, 2013, 4

[5]

Alferiev I., 2020, United States patent, Patent No. [US2020061199(A1), 20200611991]

[6]

Archakov A.I., Russia patent, Patent No. [RU2417079, 2417079]

[7] Cancer and the chemokine network [J].

Balkwill, F .

NATURE REVIEWS CANCER, 2004, 4 (07) :540-550

[8] Quo vadis nanomedicine? Foreword [J].

Barz, Matthias ;

Luxenhofer, Robert ;

Schillmeier, Michael .

NANOMEDICINE, 2015, 10 (20) :3089-3091

[9]

Benita S., 2019, United States patent, Patent No. [US10239903(B2), 102399032]

[10]

Bierbach U., 2019, United States patent, Patent No. [US2019290685(A1), 20192906851]

← 1 2 3 4 5 6 7 8 9 10 →